Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

124
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
124

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical Validation of a Multiplex Urine Biomarker Assay for Surveillance of Recurrent Bladder Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Trial design and end points in hepatocellular carcinoma: an EASL-AASLD-ILCA consensus statement.

Nature reviews. Clinical oncology·2026
Same author

Asymptomatic Lipase Elevation after Immune Checkpoint Inhibitors Reflects Pancreatic Injury with Volume Loss but Minimal Clinical Sequelae.

Pancreas·2026
Same author

Validation of Risk Models for Predicting Post-SVR HCC in Real-World Surveillance Across Global Geographic Regions.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

Impacts of a Public Health Emergency on Cancer Testing Rates, Follow-up, and Cancer Diagnosis: an Evaluation of the COVID-19 Pandemic.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2026
Same author

Colorectal cancer screening: An update to the American Cancer Society guideline, 2026.

CA: a cancer journal for clinicians·2026

Related Experiment Video

Updated: Jun 14, 2025

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

36.4K

Designing Rigorous and Efficient Clinical Utility Studies for Early Detection Biomarkers.

Yingye Zheng1, Paul D Wagner2, Amit G Singal3

  • 1Biostatistics Program, Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.

Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology
|September 3, 2024
PubMed
Summary

Demonstrating biomarker clinical utility is crucial for patient care but challenging in early detection trials. This commentary outlines recommended processes and novel adaptive designs for efficient clinical utility studies.

More Related Videos

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.4K
Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
07:40

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

16.6K

Related Experiment Videos

Last Updated: Jun 14, 2025

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

36.4K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.4K
Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
07:40

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

16.6K

Area of Science:

  • Biomedical research
  • Clinical trial design
  • Biomarker development

Background:

  • Clinical utility of biomarkers requires demonstrating positive patient outcomes through actionable clinical decisions.
  • Early detection utility trials, particularly those focused on mortality, face significant cost and time challenges.
  • Specialized design considerations are essential for accurately assessing early detection assays.

Purpose of the Study:

  • To outline a recommended process for conducting single-organ biomarker-driven clinical utility studies.
  • To present early detection utility studies within a phased biomarker development framework.
  • To discuss design aspects including biomarker test features, clinical endpoints, performance criteria, and sample size.

Main Methods:

  • Review and discussion among National Cancer Institute's Early Detection Research Network investigators.
  • Exploration of novel adaptive design approaches for enhanced trial efficiency and practicality.
  • Integration of real-world evidence, emulated trials, and mathematical modeling.

Main Results:

  • A framework for phased biomarker development and clinical utility assessment is presented.
  • Key study design elements for biomarker utility trials are detailed.
  • Adaptive designs and alternative evidence sources are proposed to overcome trial challenges.

Conclusions:

  • Establishing biomarker clinical utility necessitates rigorous study designs that address practical challenges.
  • Novel adaptive designs and the integration of real-world evidence can improve the efficiency of clinical utility trials.
  • A multi-strategy approach is recommended for successful early detection utility studies.